A Modified Low-Cost Technique of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Two Patients: a Solution for Pseudomyxoma Peritonei in the Indian Scenario?
- 35 Downloads
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have emerged as feasible treatment modalities for peritoneal dissemination (pseudomyxoma peritonei—PMP) in selected malignancies of the ovaries, appendix, colorectum, stomach, and even urinary bladder [1, 2, 3]. The time period after 2010 has seen a noticeable boost in the number of centers adopting this technique . It has been shown that removing all macroscopic tumor tissue from the peritoneal surface (residual < 2.5 mm) facilitates destruction of the residual cells by local chemotherapy, heated to 40–45 °C for maximum penetration. This approach has shown better survival and less complication rates than systemic chemotherapy administered pre-or postoperatively in the same subset of patients. Better results have been demonstrated in certain pathological subtypes of PMP like metastatic colorectal carcinoma and disseminated peritoneal adenomucinosis (DPAM) [4, 5].
Since the procedure is...
Hyperthermic intraperitoneal chemotherapy
Peritoneal cancer index
Completeness of cytoreduction
Disseminated peritoneal adenomucinosis
Rana AKS: idea, clinical contribution, editing
Agarwal N: idea, clinical contribution, writing of manuscript, and editing
Dutta S: writing of manuscript and editing
Dokania MK: writing of manuscript and editing
Goyal H: writing of manuscript and editing.
Compliance with Ethical Standards
Ethics Approval and Consent to Participate
Informed consent was taken from the patient; the study is case report which conforms to the standards of the institutional ethics committee.
Consent for Publication
Informed consent was taken from the patient.
Availability of Data and Material
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):45–57. https://doi.org/10.3978/j.issn.2078-6891.2015.111. ReviewCrossRefPubMedPubMedCentralGoogle Scholar
- 6.Bhatt A, Mehta S, Seshadri RA, Sethna K, Zaveri S, Rajan F, et al. The initial Indian experience with cytoreductive surgery and HIPEC in the treatment of peritoneal metastases. Indian J Surg Oncol. 2016;7(2):160–5. https://doi.org/10.1007/s13193-016-0500-x. Epub 2016 Feb 2CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Padmanabhan N, Kumar BR, Pookunju AP, Srinivasan A, Mahajan V. Preliminary experience and morbidity analysis of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) from a tertiary cancer center in India. J Clin Diagn Res. 2015;9(6):XC09–13. https://doi.org/10.7860/JCDR/2015/14216.6075.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Hinkle NM, MacDonald J, Sharpe JP, Dickson P, Deneve J, Munene G. Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program. Am J Surg. 2016;212:413–8. https://doi.org/10.1016/j.amjsurg.2016.01.022.CrossRefPubMedGoogle Scholar
- 12.Squires MH III, Staley CA, Knechtle W, Winer JH, Russell MC, Perez S, et al. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications. Ann Surg Oncol. 2015;22(5):1739–45. https://doi.org/10.1245/s10434-014-4025-7.CrossRefPubMedGoogle Scholar
- 13.Cravioto-Villanueva A, Cavazos M, Luna-Perez P, Martinez-Gomez H, Ramirez ML, Solorzano J, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin. Surg Today. 2016;46(8):979–84. https://doi.org/10.1007/s00595-016-1335-3.CrossRefPubMedGoogle Scholar